يعرض 1 - 10 نتائج من 41 نتيجة بحث عن '"Hendriks, A Emile J"', وقت الاستعلام: 1.44s تنقيح النتائج
  1. 1
  2. 2
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية

    المصدر: Riedmeier , M , Antonini , S R R , Brandalise , S , Costa , T E J B , Daiggi , C M , de Figueiredo , B C , de Krijger , R R , De Sá Rodrigues , K E , Deal , C , Del Rivero , J , Engstler , G , Fassnacht , M , Fernandes Luiz Canali , G C , Molina , C A F , Gonc , E N , Gültekin , M , Haak , H R , Guran , T , Hendriks A , E J , ....

  7. 7
    دورية أكاديمية

    المساهمون: HUS Children and Adolescents, Children's Hospital, Research Programs Unit, CAMM - Research Program for Clinical and Molecular Metabolism

    وصف الملف: application/pdf

    العلاقة: This clinical trial is funded by Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU) INNODIA under grant agreement no 115797. This Joint Undertaking receives support from the Union's Horizon 2020 research and innovation program and 'EFPIA', 'JDRF' and `The Leona M. and Harry B. Helmsley Charitable Trust'. The IMP is supplied by INNODIA member Sanofi. The CE-marked CGM devices are provided by DexCom (USA). supported by IMI2-JU under grant agreement No 115797 (INNODIA) and No 945268 (INNODIA HARVEST). DD was supported by the UK NIHR Cambridge Biomedical Research Centre.The sponsor is Universitaire Ziekenhuizen Leuven (UZL), Leuven, Belgium. Sponsor Number: S63466. Central Coordination is done on behalf of the sponsor by the University of Cambridge, UK (MELD-ATG@medschl.cam.ac.uk).The EudraCT Number is 2019-003265-17.; Wilhelm-Benartzi , C S , Miller , S E , Bruggraber , S , Picton , D , Wilson , M , Gatley , K , Chhabra , A , Marcovecchio , M L , Hendriks , A E J , Morobe , H , Chmura , P J , Bond , S , Aschemeier-Fuchs , B , Knip , M , Tree , T , Overbergh , L , Pall , J , Arnaud , O , Haller , M J , Nitsche , A , Schulte , A M , Mathieu , C , Mander , A & Dunger , D 2021 , ' Study protocol : Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes ' , BMJ Open , vol. 11 , no. 12 , 053669 . https://doi.org/10.1136/bmjopen-2021-053669Test; 2ea7f5a7-f008-4f85-a9ee-ab631f0269ab; http://hdl.handle.net/10138/338177Test; 000730060800005

  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: https://orca.cardiff.ac.uk/id/eprint/146010/1/e053669.full.pdfTest; Wilhelm-Benartzi, Charlotte S. orcid:0000-0003-4927-6158 orcid:0000-0003-4927-6158, Miller, Sarah E., Bruggraber, Sylvaine, Picton, Diane, Wilson, Mark, Gatley, Katrina, Chhabra, Anita, Marcovecchio, M. Loredana, Hendriks, A. Emile J., Morobé, Hilde, Chmura, Piotr Jaroslaw, Bond, Simon, Aschemeier-Fuchs, Bärbel, Knip, Mikael, Tree, Timothy, Overbergh, Lut, Pall, Jaivier, Arnaud, Olivier, Haller, Michael J., Nitsche, Almut, Schulte, Anke M., Mathieu, Chantal, Mander, Adrian https://orca.cardiff.ac.uk/view/cardiffauthors/A2472355M.htmlTest orcid:0000-0002-0742-9040 orcid:0000-0002-0742-9040 and Dunger, David 2021. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open 11 (12) , e053669. 10.1136/bmjopen-2021-053669 https://doi.org/10.1136/bmjopen-2021-053669Test file https://orca.cardiff.ac.uk/id/eprint/146010/1/e053669.full.pdfTest

  10. 10
    دورية أكاديمية